Washington, DC, June 12, 2006 New analyses from the landmark PROactive Study found that ACTOS (pioglitazone HCl), an oral antidiabetic medication, significantly reduced the occurrence of major adverse cardiovascular events (MACE) such as heart attacks (excluding silent heart attacks), nonfatal stroke, acute coronary syndrome (ACS) and cardiovascular death in high-risk patients with type 2 diabetes. Additionally, results showed that ACTOS significantly decreased the progression to permanent insulin use. These results were presented as three separate abstracts at the American Diabetes Association (ADA) 66th Annual Scientific Sessions.
"What is unique about these new data is that while earlier PROactive results found a combined risk reduction of heart attack stroke and death by 16 percent in high-risk patients treated with ACTOS, we saw a greater risk reduction when we looked at the wider scope of major adverse cardiovascular events, in this high-risk population," said Erland Erdmann, M.D., chairman of the PROactive Executive Committee, and director of the Clinic III for Internal Medicine, University of Cologne, Germany.
"Separate analyses suggest a significant decrease in the amount of insulin needed, as well as a delay in the need for permanent insulin use among patients taking ACTOS," said Robert Spanheimer, M.D., medical director for diabetes and metabolism at Takeda Pharmaceuticals North America, Inc. "As type 2 diabetes is a progressive disease requiring multiple therapies, many patients eventually need supplementary insulin to manage their condition. For patients with type 2 diabetes and established cardiovascular disease, these results could lead to the potential for less dependence on daily insulin use."
Major Adverse Cardiac Events
Composite endpoints of cardiovascular events are standard measures for comparing treatments in large outcome studies and are referred to as major adverse cardiovascular events (MACE). Page: 1 2 3 Related medicine news :1
Contact: Amy Losak
. Stem cell transplantation procedure results in long-term survival for amyloidosis patients2
. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma3
. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer4
. Targeted, oral agent Enzastaurin shows favorable results5
. Childhood obesity intervention shows promising results6
. Alpharma presents positive pharmacokinetic study results7
. UCSF brain tumor vaccine trial shows promising results8
. The eyes have it -- Autism research yields surprising results9
. ACP: Residency match results for internal medicine underscore need to redesign primary care10
. Positive results more likely from industry-funded breast cancer trials11
. Preclinical results of Geovaxs AIDS vaccines demonstrate potential to protect against disease